Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

• Status: Unknown status
• Trial end date: 2017-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yanqing Li
• Treatments: Amoxicillin; Anti-Infective Agents; Clarithromycin; Furazolidone; Levofloxacin; Ofloxacin; Tetracycline; Tinidazole

Criteria

Inclusion Criteria:

• Consecutive patients who are 18-70 years old with persistent H. pylori infection after first or second line treatment attempts.

Exclusion Criteria:

• Enable to undergo upper endoscopy;

• Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;

• Known or suspected allergy to study medications;

• Taking bismuth and antibiotics in the previous four weeks, or taking proton pump inhibitor and H2-receptor blockers in the previous two weeks;

• Currently pregnant or lactating

• Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.